University of Colorado Denver-Anschutz Medical Campus, Aurora, CO, USA.
Cardinal Health Specialty Solutions, 7000 Cardinal Place, Dublin, OH, USA.
Future Oncol. 2022 Feb;18(5):553-564. doi: 10.2217/fon-2021-1176. Epub 2021 Nov 17.
To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Disease response was 78.6 and 51.7% for pomalidomide (n = 126) and nonpomalidomide cohorts (n = 174), respectively (p < 0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p < 0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7 months for nonpomalidomide cohort (log-rank p < 0.01). Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.
为了在真实世界、社区实践中使用回顾性数据库分析来证明泊马度胺对一线来那度胺治疗后复发/难治性多发性骨髓瘤（RRMM）的疗效。美国社区肿瘤学家确定了在一线来那度胺治疗后接受或未接受泊马度胺治疗的 RRMM 患者。比较疾病缓解率（≥非常好的部分缓解）和无进展生存期。泊马度胺组（n=126）和非泊马度胺组（n=174）的疾病缓解率分别为 78.6%和 51.7%（p<0.0001）。泊马度胺组的反应多变量调整优势比为 4.5 倍（p<0.0001）。泊马度胺组的中位无进展生存期未达到，而非泊马度胺组为 16.7 个月（对数秩检验 p<0.01）。在 RRMM 中接受来那度胺诱导治疗后，泊马度胺是一种有效的治疗方法。
